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ABSTRACT
Objectives: To find evidence, either corroborating or
refuting, for many persisting beliefs regarding the
feasibility of carrying out surgical randomised
controlled trials with a placebo arm, with emphasis on
the challenges related to recruitment, funding,
anaesthesia or blinding.
Design: Systematic review.
Data sources and study selection: The analysis
involved studies published between 1959 and 2014
that were identified during an earlier systematic review
of benefits and harms of placebo-controlled surgical
trials published in 2014.
Results: 63 trials were included in the review. The
main problem reported in many trials was a very slow
recruitment rate, mainly due to the difficulty in finding
eligible patients. Existing placebo trials were funded
equally often from commercial and non-commercial
sources. General anaesthesia or sedation was used in
41% of studies. Among the reviewed trials, 81% were
double-blinded, and 19% were single-blinded. Across
the reviewed trials, 96% (range 50–100%) of
randomised patients completed the study. The
withdrawal rate during the study was similar in the
surgical and in the placebo groups.
Conclusions: This review demonstrated that placebo-
controlled surgical trials are feasible, at least for
procedures with a lower level of invasiveness, but also
that recruitment is difficult. Many of the presumed
challenges to undertaking such trials, for example,
funding, anaesthesia or blinding of patients and
assessors, were not reported as obstacles to
completion in any of the reviewed trials.
INTRODUCTION
Progress in surgery is based on practical
experience.1 Surgical randomised controlled
trials (RCTs) are uncommon;2 only about
15% of published RCTs are related to surgi-
cal interventions.3 Novel procedures tend to
be developed through an iterative process of
trial and error,4 and only 24% of the cur-
rently used surgical therapies are supported
by results of RCTs.1
Apart from not being necessary for
approval of new treatment,5 several reasons
have been mentioned in the literature that
may explain why surgical RCTs are scarce.
Such studies are perceived as expensive2 6
and unlikely to attract funding.3 5 7 They are
considered to be difﬁcult to design and
conduct because of challenges posed by ran-
domisation, blinding, differences in skills
and experience of surgeons, variability of
patients, as well as lack of consensus on surgi-
cal outcomes.1 2 6–8 Moreover, patient
recruitment is also believed to be a
problem.6 The inclusion of a placebo control
adds another level of complexity to a RCT.6 9
For example, some authors suggest that
many patients may be unwilling to undergo
an invasive procedure if there is no clear
direct beneﬁt to them, which may result in
slow recruitment.6 Others believe blinding of
patients and outcome assessors is not feas-
ible, and that the surgeon can never be
blinded.10 As a result of that, very few inter-
ventional procedures have been validated
using a placebo-controlled RCT.1 2 5 9 11 12
It is important to note that some of these
opinions come from personal experience
Strengths and limitations of this study
▪ Review of all published surgical randomised con-
trolled trials (RCTs) with a placebo arm, span-
ning the years 1959 to 2014.
▪ Owing to the nature of this review, we could not
investigate the obstacles that prevented initiation
or completion of trials and, subsequently, our
observations are limited to the successfully pub-
lished trials. However, this review of all pub-
lished trials provides different evidence than a
report from a single discontinued trial.
▪ Many of the problems reported in reviewed trials
are not unique to placebo-controlled surgical
trials, but are also relevant to other surgical trials
and randomised controlled trials in general.
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from a single trial, while others are just perceptions and
assumptions. There have also been many publications
discussing placebo in surgery that concentrate on ethical
concerns, such as general equipoise and minimising the
risks,13 14 and on conceptual problems, for example,
whether surgeons will be willing to test efﬁcacy of an
already established procedure.10 15 However, very little
has been written on the methodological challenges of
such studies6 16 and, to the best of our knowledge, no
one has attempted to summarise the evidence from all
the published placebo-controlled surgical trials.
When we previously performed a systematic review
examining the harms and beneﬁts of placebo-controlled
surgical RCTs, we found that there clearly are obstacles
to completing such trials, as less than a hundred have
been published between 1959 and 2013.12 Therefore, we
conducted a secondary review of these studies to ﬁnd
evidence corroborating or refuting persisting beliefs
regarding the feasibility of carrying out placebo-
controlled surgical trials.
METHODS
Selection criteria
The criteria used to select placebo-controlled surgical
RCTs have been described previously.12 In brief, studies
were eligible if they were randomised trials in which the
efﬁcacy of surgery was compared with placebo. Surgery
was deﬁned as any interventional procedure that
changes the anatomy and requires a skin incision or the
use of endoscopic techniques; dental studies were
excluded. We used the term ‘placebo’ to refer to a surgi-
cal placebo, a sham surgery, or a procedure intended to
mimic the active intervention. A quasi-placebo, that is, a
diagnostic procedure that could imitate the surgery, was
also included. The important criterion was that patients
were under general anaesthesia or blinded in some
other way, and could not distinguish whether they
underwent the actual surgery or placebo. We did not
limit the inclusion criteria to any particular condition,
patient group, intervention, or type of outcome. We
excluded studies investigating anaesthesia or other
pharmacological substances used perioperatively.
In this review, we used the term ‘surgical placebo’.
The word ‘sham’ is preferred by some authors because
surgical placebo has to involve an imitation of the inves-
tigated intervention in order to resemble it closely;
therefore, it is different from an inactive ‘sugar pill’
placebo used in pharmacological trials.17 The word
‘sham’ has negative associations, and it suggests that a
procedure is fake and deceitful; however, in many trials,
the placebo involved an accepted surgical procedure
such as endoscopy or arthroscopy, which was used also
for diagnostic purposes with real beneﬁts to the patients.
Search strategy
We searched the MEDLINE, EMBASE and the
Cochrane Central Register of Controlled Trials
databases from the date of their inception to 14
November 2013, with no restriction on language. We
did not systematically search for studies reported only
as conference abstracts. Search terms were published
previously.12
Three reviewers (KW, IR and BJFD) independently
screened the initial set of records identiﬁed from the
search, and then screened the full text of any potentially
relevant articles. Each reviewer assessed the eligibility of
each study, and the ﬁnal list of included studies was
agreed by consensus. Moreover, we searched
ClinicalTrials.gov (on 14 November 2013), a database of
registered randomised clinical trials, to identify any
recently completed or ongoing studies. On 15 June
2014, we checked whether results of any of the trials
identiﬁed in the ClinicalTrials.gov database have been
published since the original search.
Dealing with duplicate publications
When there were several articles reporting outcomes
from a single trial, that is, with the same authors, loca-
tion, patient population and recruitment dates, we
only included the paper reporting the primary
outcome for the trial, and excluded pilot and
follow-up reports.
Data extraction
We used a standardised data extraction form to collect
information about the characteristics of each study
including: year of publication, country in which the
trial was conducted, funding source, details of the
active and placebo intervention as well as the type of
anaesthesia, blinding, number of patients who were
assessed, eligible, randomised and who declined partici-
pation, as well as those who completed the trial. To
reduce errors, the three review authors (KW, IR and
BJFD) extracted data separately and checked the entries
for consistency; a single set of data was agreed by all
three reviewers.
Data synthesis
We have performed a descriptive analysis of the
characteristics of each individual study and presented
data in a table.
RESULTS
Study selection
We analysed the studies identiﬁed as a part of the sys-
tematic review on harms and beneﬁts, including seven
trials that were excluded from the systematic review due
to lack of a direct comparison between the surgical and
the placebo group. We also checked whether the trials
identiﬁed in the ClinicalTrials.gov database had their
results published between November 2013 and June
2014, and found three additional trials.18–20 This
resulted in 63 full-text articles, which were included in
this review (ﬁgure 1).
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Placebo-controlled surgical RCT characteristics
The number of published placebo-controlled surgical
trials was small; however, 73% (n=46/63) of included
RCTs were published after the year 2000, suggesting an
increasing interest in performing such studies. Half the
trials (n=35/63, 55%) used a key-hole surgery, including
endoscopy (n=28/63), laparoscopy (n=4/63), arthros-
copy (n=2/63) and bronchoscopy (n=1/63). The
remaining trials involved other types of minimally inva-
sive interventions, for example, using catheters for vascu-
lar access, or needles for injection of fat or exogenous
materials to remodel tissue. Very few studies investigated
open techniques, such as exposure of the internal
mammary artery (n=2/63), or exposure of scalp muscles
(n=1/63). Fifteen trials used implants and an additional
seven used gastric balloons or bubbles (characteristics of
the reviewed trials are presented in online supplemen-
tary appendix 1).
Funding sources
One-third of the studies (n=21/63, 33%) were non-
commercially funded, and almost as many were funded
by a commercial company (n=18/63, 29%), often the
manufacturer of the implant or the endoscope. The
source of funding in the remaining studies (n=24/63,
38%) was not reported.
Over half the trials were undertaken in the USA
(n=35/63, 56%), the others were in Canada, the UK,
Germany, The Netherlands, Belgium, Italy, Finland,
Sweden, Portugal, Norway, Greece, Denmark, Australia
and Brazil.
Figure 1 PRISMA flow diagram.
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Sample size
The majority (n=47/63, 75%) of the identiﬁed studies
were small, with fewer than 100 participants. The
median number of patients randomised in a trial was 61
(IQR 66, range 10–298).
About half the RCTs (n=33/63; 52%) reported a
formal sample size calculation, but only a quarter (n=16/
63) allowed for dropouts and attrition. Most of the trials
that included a sample size calculation (n=23/33, 70%)
attained their prespeciﬁed sample size (without account-
ing for attrition). Ten trials under-recruited, such that
the number of randomised patients was lower than the
calculated sample size. All 10 trials were terminated early:
three due to slow recruitment,21–23 one because at the
interim analysis the surgery was highly effective,24 and
two because at the interim analysis the active procedure
lacked efﬁcacy.18 25 Two studies were stopped because of
serious adverse events either in the trial26 or at another
centre using a similar procedure.27 One trial was termi-
nated when the sponsoring company was sold.28 Finally,
one study was stopped because the investigated proced-
ure was approved as a standard care and the equipoise
ceased to exist, despite the fact that the study did not
show its superiority over placebo.29 Finally, one trial
recruited the intended sample size, but due to a high
drop-out rate the number of patients who completed the
trial was lower than the required sample size.30
Recruitment and screening
Recruitment, sometimes as slow as 1–2 patients per
month,21 31 was a common problem,18 21 27–35 and was
the reason for an early termination of three trials.21–23
Many of the analysed studies did not provide any
details about screening and recruitment; they either
stated that they recruited consecutive patients fulﬁlling
the criteria,21 or that they randomised patients who were
willing to participate and were eligible.36 About
one-third of the trials speciﬁed the number of screened
(n=24/63, 38%) and eligible patients (n=27/63, 43%),
and stated how many patients declined participation or
withdrew before the treatment (n=22/63, 34%); only
one-ﬁfth of the trials (n=13/63, 21%) reported all three
numbers (see online supplementary appendix 1). The
available data suggest that the initial assessment of
eligibility was the main obstacle in recruitment as
patients did not meet the inclusion criteria or were not
eligible due to exclusion criteria.
On average, it was necessary to screen more than ﬁve
patients in order to randomise one, but three in four eli-
gible patients started the trial (table 1). The number of
patients who had to be screened before the necessary
group was recruited varied greatly. This variance was, at
least partly, related to the method of identifying poten-
tial participants. The trial with the largest number of
screened patients recruited participants by using TV and
newspaper advertising: out of 4523 screened patients
only 260 were eligible and were willing to participate;
however, 196 had negative discography, and only 64
patients were randomised.23 More targeted recruitment
from specialist centres had much higher success rates,
but often required a multisite effort.35
Many trials had additional inclusion and exclusion cri-
teria that could only be veriﬁed after the patient entered
the trial, for example, a veriﬁcation of diagnosis by posi-
tive ﬁndings during the endoscopy, or on diagnostic
imaging. As a consequence of this, many patients were
excluded because either they did not have the investi-
gated condition or they had some concomitant condi-
tion that precluded their participation in the trial and,
sometimes, required appropriate treatment. Moreover,
any technical complications during the assessment or
study procedures potentially resulted in patients’
drop-out. For example, in the trial on laparoscopic adhe-
siolysis for abdominal pain by Swank and colleagues,32
nine patients did not have adhesions, one of them had a
hernia and was treated laparoscopically, three patients
had stricturing adhesions that required therapeutic
adhesiolysis, and in one instance a pneumoperitoneum
could not be achieved; therefore, out of 121 assessed
patients, 13 were excluded during laparoscopy.
Fluctuating symptoms were a problem in a few studies,
for example, patients became asymptomatic while waiting
for the procedure and had to be excluded from the
trial,19 or did not report symptoms during the study visit,
and did not undergo the treatment, but were included in
the intention-to-treat analysis.37 This problem also com-
plicated the post-treatment assessment,38 especially that
only one trial included an observational control group.39
Table 1 Participants flow through the reviewed trials as a percentage of the number of patients who were randomised into
each trial
Number of studies
Median per cent of
sample randomised
First and third
quartile (%)
Minimum and
maximum (%)
Screened 24 530 243, 773 100, 7067
Eligible 27 132 108, 172 100, 448
Declined 22 18 8, 144 3, 4942
Sample size 33 96 90, 110 49, 323
Outcome assessed 61 96 90, 100 52, 100
‘Number of studies’ refers to the number of trials that provided relevant data. Trials terminated early are included in these analyses. ‘Sample
size’ refers to the sample size required to reach statistical power, not inflated to account for drop-outs. ‘Outcome assessed’ refers to total
number of patients, in both arms. The denominator is the number of patients actually randomised into each trial.
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Refusal to participate
Some of the approached patients declined participation
in the trial, withdrew their initial consent, refused to be
randomised or to comply with the requirements of the
protocol, and had a strong preference for one of
the treatment options. Most of the trials did not report
the reasons for patients’ refusal to participate, and the
available data did not allow us to quantify the percentage
of patients who refused to enter the study. Only 22
reviewed trials stated the number of patients who
declined to participate, but it was not always clear
whether these numbers referred to patients at the
screening stage or to patients already identiﬁed as eli-
gible. The median percentage of patients who declined
participation as a percentage of randomised patients was
18%, and varied from 3% to 4842%. It is important to
note, that the two trials with high numbers of patients
refusing to participate investigated vertebroplasty, which,
at the time, was an established procedure; therefore,
patients could easily receive the treatment from a differ-
ent medical centre, without participating in a trial.34 35
Patient retention
In general, recruitment was more problematic than
retention and, once recruited, patients usually remained
in the trial. Across the reviewed trials, 96% of rando-
mised patients completed the study (table 1). A lower
completion rate in ﬁve trials was caused by an early ter-
mination25 29 40 as well as withdrawals or change of
patients’ health status.41 42 In general, the predicted
attrition, by which the required sample size was inﬂated
to account for drop-outs, was 10% (median) with the
range from 5% to 24%, whereas the actual patients’ attri-
tion between randomisation and outcome assessment
was 4% (range 0–50%).
The completion rate was similar in the active and in the
placebo arm, except for two trials: one18 where ﬁve times
as many patients were lost to follow-up in the active group
than in the placebo group, and one30 where the drop-out
rate was three times higher in the placebo group. Neither
of these studies could explain this difference.
Most of the drop-outs occurred before randomisation.
The reported reasons for drop-out during the trial were
withdrawals, loss to follow-up, or discontinuation without
known cause,20 39 41 43 44 patients’ request to be
unblinded,24 adverse events,25 26 change of medical
status such as pregnancy or concurrent illness.23 45 46 A
long wait between the screening and procedure did not
necessary result in patient withdrawal.43 A variable
reporting did not allow us to evaluate quantitatively the
reasons for drop-outs.
Blinding was possible, and some studies attempted to
blind surgeons
In 12 trials (19%), only patients were blinded, but in the
majority of RCTs (n=51/63, 81%) both patients and
outcome assessors were blinded; including three trials,
in which there was also an attempt to blind the operator.
For example, in two trials, the implant delivery system
was preloaded by the manufacturer—the devices looked
identical but only one contained an implant.28 47 In
another trial, the surgeon placed the catheter but then
handed the procedure over to a technician who deliv-
ered the treatment according to the randomisation.21
Authors of the reviewed trials went to great lengths to
imitate the visual, verbal and physical cues, and to make
the placebo as similar as possible to the active proced-
ure. For example, patients wore goggles, or had the view
obscured, so that they could not see the device.48 The
preparation for the placebo intervention was done in
the same way as for the active procedure.35 49 Similar
verbal instructions were given as during the surgery,42 50
and there were attempts to imitate the noises made by
the devices.51 In trials that used exogenous substances,
the container was opened so that the distinct smell was
also present during the placebo condition.35 Some
researchers attempted to keep the duration of the pro-
cedure the same in both arms,39 43 52 whereas others
thought that it was more ethical to shorten the placebo
intervention.31
Very few studies assessed the success of blinding.
Often authors thought that it was reasonable to assume
that patients in the study were not able to distinguish
between placebo and surgery due to minimally invasive
characteristics of the procedure, and minimally post-
operative treatment-related symptoms.53 54 In one trial,
the post-treatment symptoms were believed to be a sign
of correctly placed effective gastroplication, as patients
with these symptoms had better outcomes.39 Blinding
was reported as successful in n=13/63 (21%) studies. In
four trials,35 42 55 56 a larger proportion of patients in
the active group guessed correctly; however, the placebo
group did not guess the treatment allocation. In one
study, two patients were deﬁnitely unblinded early due
to implant extrusion.57
Anaesthesia
In the reviewed trials, patients in both groups received
some type of anaesthesia. General anaesthesia or sed-
ation was used in n=26/63 trials (41%), including one
trial in which general anaesthesia was used in the surgi-
cal group, but patients in the placebo group were
sedated without intubation.29 Local analgesia was used
in n=16/63 (25%) RCTs, four studies used a mixture of
methods, and n=17/63 (27%) trials did not describe the
type of anaesthesia used. None of the trials reported
that anaesthesia was a barrier in conducting their study.
DISCUSSION
This review has demonstrated that surgical RCTs with a
placebo arm are feasible, at least for procedures with a
lower level of invasiveness. Many of the presumed chal-
lenges, such as funding, anaesthesia or blinding of
patients and assessors, were not reported as obstacles in
any of the reviewed trials. The main hurdle in
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completing a trial was ﬁnding a sufﬁcient number of eli-
gible patients.
We found that, although, there were very few surgical
RCTs with a placebo arm published between 1959 and
2014, there was a rising trend. This may be related to an
increasing interest in placebo and placebo-controlled
trials in general,58 or to the increasing popularity of
minimally invasive procedures since 1980s. The latter
explanation is supported by the fact that most of the
reviewed trials used some type of key-hole surgery.
The analysed placebo-controlled trials were funded
equally often by industry as by non-commercial funding
bodies. The number of commercially funded older trials
may be underestimated in our review because surgical
RCTs funded by industry have lower odds of being pub-
lished.59 However, the recent trials are registered in the
ClinicalTrials.gov database and would have been identi-
ﬁed. The distribution of the source of funding was
similar to that described by other authors.11 This is
encouraging, as it shows that there is an interest within
the industry to validate the efﬁcacy of their products,
and also that the non-commercial bodies are willing to
investigate the efﬁcacy of surgical procedures. The costs
of running surgical RCTs are high,2 but in the long run,
preferential funding of treatment with proven efﬁcacy
may help to improve the allocation of resources and to
lower the costs of healthcare.60 For example, the trial by
Moseley and colleagues52 demonstrated that arthro-
scopic surgery had no beneﬁts because the outcomes in
the arthroscopic debridement arm and the lavage arm
were not better than in the placebo group and, conse-
quently, there was a decline in the use of this procedure
for knee osteoarthritis.61
Recruitment into placebo-controlled surgical trials was
possible but was often very slow, and resulted in an early
termination of several trials. Slow recruitment is the
most frequent reason for discontinuation of RCTs,
including surgical RCTs. For example, 21% of reviewed
surgical RCTs were discontinued early, and 44% of these
were due to problems with recruitment.59 Authors often
underappreciate the fact that the target population in
surgical trials is small; therefore, it may be challenging
to recruit a required number of patients in a reasonable
period of time.2 The right timing of a trial may also
affect its completion,7 for example, initiating a trial too
early in the intervention’s development may result in
more procedure-related adverse events,26 whereas, when
a procedure has been already established, like vertebro-
plasty, it may be difﬁcult to recruit participants.34 35
In the reviewed trials, the number of patients who had
to be screened in order to recruit a necessary partici-
pant group was larger than in other RCTs, but the pro-
portion of eligible patients who started the study was
comparable with other types of RCTs.62 This is another
argument suggesting that the main challenge in those
trials was ﬁnding suitable patients rather than persuad-
ing potential participants to enter the trial, and this is a
bigger problem than in other types of RCTs.62
Reporting of the recruitment process and eligibility was
generally poor and often difﬁcult to interpret, as the
reviewed studies usually did not describe in detail why
eligible patients did not enter the trial, which is in line
with observations from other reviews.62 The quality of
reporting in analysed RCTs was poor, but this is a known
problem in surgical trials.7 62
There is an assumption that patients are unwilling to
take part in surgical RCTs, especially patients in severe
pain.63 Interestingly, in the trial by Moseley and collea-
gues,52 patients in more pain were more likely to agree
to participate. Also patients tend to choose the new
treatment even if it was not proven to be superior over
placebo. For example, in the trials on Parkinson’s
disease, patients actually opted for the transplantation
when they were given a choice after the end of the trial,
despite the fact that it was not demonstrated to be more
effective than placebo.49 In a recent orthopaedic
placebo-controlled RCT, patients were willing to partici-
pate, and screening failures were a larger problem than
refusals or withdrawals.16 The clinical characteristics of
patients who entered into a placebo-controlled RCT
were comparable to the non-enrolment group, as well as
to patients in other trials.16
Only about half the published trials reported a sample
size calculation, which is in line with another review of
surgical trials, which found that sample size calculations
were reported only in 63% of RCTs.11 However, it is
important to note that some of the reviewed trials were
published before the CONSORT (Consolidated
Standards of Reporting Trials) were introduced, and
before the sample size calculation became required by
the board review. Some trials were small because of the
author’s assumption that surgical studies have a large
effect size; therefore, inferring that a smaller sample size
is required in surgical trials than in drug trials.47 64
However, surgical RCTs may require larger numbers of
patients to reach the required sample size.65 Recent
systematic reviews demonstrated that the effect size of
the surgical procedure in comparison with placebo in
the existing trials was often small.12 66 It is likely that the
apparent lack of difference between the active treatment
and placebo might have been related to the small
sample size and the effect not reaching the statistical sig-
niﬁcances.47 67 68 It might be also caused by a large
placebo effect; however, the magnitude of the placebo
effect in surgical procedures is unknown. The magni-
tude of response in the placebo arm is related not only
to the placebo effect, that is, response directly related to
the placebo intervention, but also to non-speciﬁc
changes, such as regression to the mean, natural history
of disease, or effect of participation in the trial.69 Only
one reviewed trial included a non-interventional group
to control for these non-speciﬁc effects.39
A placebo procedure can successfully imitate a minim-
ally invasive surgery. Blinding in interventional trials is
more challenging than in pharmaceutical ones;11 70
however, there are many strategies to blind the patients
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and outcome assessors,70 and the reviewed trials often
used ingenious methods to achieve blinding. The
success of blinding was rarely assessed, but it is not
necessary, according to the current reporting standards.
The requirement to assess blinding was removed from
the CONSORT checklist because of evidence that testing
for blindness is not valid because it cannot distinguish
the success of blinding from ‘hunches’ about the treat-
ment’s efﬁcacy.71
Blinding of patients and outcome assessors is especially
important if the outcomes are subjective or difﬁcult to
quantify.72 Softer outcomes are difﬁcult to evaluate in
unblinded trials due to patient-related or assessor-related
bias, which may distort the treatment effect.73 74 In this
analysis, we have demonstrated that the withdrawal rate
was generally low and was similar in the active and the
placebo groups. This provides supporting evidence that
blinding reduces the attrition bias, as patients do not
know to which treatment they had been allocated.75
Future implications for clinicians and unanswered
questions
What remains to be understood is why eligible patients
decline participation or withdraw their consent before
randomisation.76 Addressing these issues may improve
the recruitment procedure in future trials.
There is also a need to estimate the magnitude of
placebo effect in interventional trials. Several authors
have highlighted the fact12 65 66 that for softer outcome
measures, the magnitude of placebo effect in surgical
trials is underestimated while the effect size of the surgi-
cal intervention is overestimated and, as a result of that,
many trials do not recruit sufﬁcient numbers of patients
to detect differences between the effects of surgery and
placebo.
Journals should encourage authors to report the
details of patient recruitment and allocation, including
the reasons for withdrawals and screening failures. Data
like this are very useful when planning future trials.
There has been an improvement in the reporting
quality of recent trials,20 and these guidelines were
included in the CONSORT extension for non-
pharmacological interventions.77
In conclusion, not every surgical procedure has a
viable placebo control; however, surgical RCTs with a
placebo arm are feasible for many less invasive proce-
dures. Although placebo-controlled surgical RCTs are
challenging, they should not be dismissed as a potential
trial design in surgical research. There is a need to
better understand the factors that make those trials chal-
lenging so that future trials are not terminated early, and
contribute good quality evidence to surgical practice.
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